Publication/Presentation Date

1-1-2014

Abstract

Lenalidomide belongs to a novel class of drugs called Immunomodulators which are now being used for the treatment of plasma cell dyscrasias with variable degrees of efficacy and toxicity. Though Second Primary Malignancies (SPM) have been a concern with its use, the benefits of the treatment outweigh the risks. The leukemogenic risk seems to be potentiated especially when combined with alkylating agents and the SPMs documented are predominantly myeloblastic. To date there are no reported cases of new lymphocytic leukemias in AL amyloidosis, regardless of whether undergone treatment or not. We present a case of AL amylodosis who was treated with lenalidomide and subsequently developed acute lymphoblastic leukemia.

Volume

7

Issue

5

First Page

2683

Last Page

2689

ISSN

1936-2625

Comments

This is also available through PubMed Central

Disciplines

Hematology | Hemic and Lymphatic Diseases | Medicine and Health Sciences | Oncology | Pathology

PubMedID

24966987

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Pathology and Laboratory Medicine

Document Type

Article

Share

COinS